No Data
European Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading
BTIG Maintains Mereo BioPharma(MREO.US) With Buy Rating, Maintains Target Price $6
LifeSci Capital Maintains Mereo BioPharma(MREO.US) With Buy Rating, Maintains Target Price $10
Needham Maintains Mereo BioPharma(MREO.US) With Buy Rating, Maintains Target Price $7
Optimism in Mereo Biopharma: Strong Phase II Results and Strategic Advancements Fuel Buy Rating
Mereo BioPharma Updates on Phase 3 Study of Setrusumab and Positive EMA Opinion for Alvelestat in Rare Diseases